PFKFB3 [41], HK2 [42], and PKM2 [43], as the key enzymes of glycolysis, have been shown to be overexpressed in sorafenib resistant HCC cell lines to increase glycolysis flux, which were silenced for contributing to synergetic effect with sorafenib. Here, HK2 is linked to hepatocellular carcinoma.